{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:09:40Z","timestamp":1780319380813,"version":"3.54.1"},"reference-count":135,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Differentiation therapy is a cornerstone in treating hematologic malignancies, particularly acute myeloid leukemia (AML). Differentiation agents target molecular defects blocking myeloid differentiation. However, rapid differentiation can precipitate a life-threatening complication, differentiation syndrome (DS). DS manifests with fever, pulmonary infiltrates, pleural or pericardial effusions, hypotension, and organ dysfunction, often mimicking sepsis or infection. Early recognition in the emergency department (ED) is critical to mitigate morbidity and mortality. This review aims to provide emergency clinicians with practical strategies for the timely identification and management of DS in patients undergoing differentiation therapy. Discussion: Suspicion for DS should be heightened in patients with acute promyelocytic leukemia (M3 AML) who recently started induction chemotherapy, including all-trans retinoic acid or arsenic trioxide, and in those with non-M3 AML receiving differentiation agents (i.e., isocitrate dehydrogenase inhibitors, menin inhibitors, FMS-like tyrosine kinase 3 inhibitors). Imaging can identify pulmonary infiltrates, effusions, and other cardiopulmonary manifestations. Laboratory workups should include complete blood counts with differentials, serum chemistries, cardiac biomarkers, and sepsis panels to exclude infection. Electrocardiography is advised for patients on QT-prolonging agents. Management emphasizes prompt initiation of high-dose corticosteroids and supportive measures such as blood pressure support, intravascular volume optimization, and oxygen therapy or ventilatory support. Multidisciplinary coordination with oncology, hematology, and critical care teams is important to tailor plans and monitor complications. Conclusions: DS represents a diagnostic challenge in the ED due to its nonspecific presentation and mimicry of infection. A high index of suspicion, combined with targeted imaging, laboratory evaluation, and early corticosteroid therapy, can improve outcomes.<\/jats:p>","DOI":"10.3390\/cancers18111798","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:19:42Z","timestamp":1780316382000},"page":"1798","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Identification and Management of Differentiation Syndrome in Emergency Settings: A Narrative Review"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2122-5367","authenticated-orcid":false,"given":"Gregory A.","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA"},{"name":"Emergency Care Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4151-3779","authenticated-orcid":false,"given":"Tareg","family":"Bey","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Stroh","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0063-8461","authenticated-orcid":false,"given":"Aiham","family":"Qdaisat","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5170-0822","authenticated-orcid":false,"given":"Sai-Ching J.","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7326\/0003-4819-117-4-292","article-title":"The \u201cRetinoic Acid Syndrome\u201d in Acute Promyelocytic Leukemia","volume":"117","author":"Frankel","year":"1992","journal-title":"Ann. Intern. Med."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Woods, A.C., and Norsworthy, K.J. (2023). Differentiation Syndrome in Acute Leukemia: APL and Beyond. Cancers, 15.","DOI":"10.3390\/cancers15194767"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1365-2710.2008.00935.x","article-title":"Retinoic acid syndrome: A review","volume":"33","author":"Patatanian","year":"2008","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1182\/bloodadvances.2021004789","article-title":"Characteristics and predictors of early hospital deaths in newly diagnosed APL: A 13-year population-wide study","volume":"5","author":"Gill","year":"2021","journal-title":"Blood Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ajh.26142","article-title":"Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia","volume":"96","author":"Fathi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2010.08325.x","article-title":"Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia","volume":"151","author":"Luesink","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1182\/blood-2009-02-204834","article-title":"Chemokine induction by all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia: Triggering the differentiation syndrome","volume":"114","author":"Luesink","year":"2009","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/cup.13780","article-title":"Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation","volume":"47","author":"Tabata","year":"2020","journal-title":"J. Cutan. Pathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.3324\/haematol.10607","article-title":"Adhesion molecules and differentiation syndrome: Phenotypic and functional analysis of the effect of ATRA, As2O3, phenylbutyrate, and G-CSF in acute promyelocytic leukemia","volume":"92","author":"Tamarozzi","year":"2007","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1046\/j.1365-2141.1999.01671.x","article-title":"All-trans retinoic acid regulates adhesion mechanism and transmigration of the acute promyelocytic leukaemia cell line NB-4 under physiologic flow","volume":"107","author":"Brown","year":"1999","journal-title":"Br. J. Haematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1182\/blood.V90.7.2747","article-title":"Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2","volume":"90","author":"Larson","year":"1997","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1046\/j.1365-2141.1996.4911029.x","article-title":"All-trans-Retinoic Acid Increases Adhesion to Endothelium of the Human Promyelocytic Leukaemia Cell Line NB4","volume":"93","author":"Marchetti","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/sj.leu.2403284","article-title":"Retinoic acid syndrome in NOD\/scid mice induced by injecting an acute promyelocytic leukemia cell line","volume":"18","author":"Ninomiya","year":"2004","journal-title":"Leukemia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1182\/blood-2010-01-266064","article-title":"Tissue transglutaminase contributes to the all-trans-retinoic acid\u2013induced differentiation syndrome phenotype in the NB4 model of acute promyelocytic leukemia","volume":"116","author":"Balajthy","year":"2010","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3324\/haematol.2018.192823","article-title":"Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-\u03baB activation","volume":"104","author":"Jambrovics","year":"2018","journal-title":"Haematologica"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1196\/annals.1420.016","article-title":"Regulation of Endothelial Junctional Permeability","volume":"1123","author":"Vandenbroucke","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"109485","DOI":"10.1016\/j.cellsig.2019.109485","article-title":"Endothelial tight junctions and their regulatory signaling pathways in vascular homeostasis and disease","volume":"66","author":"Cong","year":"2020","journal-title":"Cell. Signal."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"7210","DOI":"10.2741\/3223","article-title":"Oxidative stress-induced disruption of epithelial and endothelial tight junctions","volume":"13","author":"Rao","year":"2008","journal-title":"Front. Biosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/j.biocel.2003.08.007","article-title":"Regulation of tight junctions and loss of barrier function in pathophysiology","volume":"36","author":"Harhaj","year":"2004","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"21036","DOI":"10.1074\/jbc.M109.016766","article-title":"Occludin Phosphorylation and Ubiquitination Regulate Tight Junction Trafficking and Vascular Endothelial Growth Factor-induced Permeability","volume":"284","author":"Murakami","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s10637-025-01556-1","article-title":"Understanding the differentiation syndrome in acute promyelocytic leukemia: A comprehensive updated review","volume":"43","author":"Damaj","year":"2025","journal-title":"Investig. New Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1182\/blood-2013-10-512640","article-title":"How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia","volume":"123","author":"Sanz","year":"2014","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"11935","DOI":"10.1038\/s41598-019-47937-4","article-title":"Progressive hyperleukocytosis is a relevant predictive marker for differentiation syndrome, early death, and subsequent relapse in acute promyelocytic leukemia","volume":"9","author":"Yoon","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1007\/s00277-024-05776-y","article-title":"Early predictor for differentiation syndrome in newly diagnosed acute promyelocytic leukaemia patients treated with single-agent arsenic trioxide","volume":"103","author":"Gao","year":"2024","journal-title":"Ann. Hematol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/bjh.19763","article-title":"Leucocytosis during all-trans retinoic acid and arsenic trioxide treatment in acute promyelocytic leukaemia","volume":"205","author":"Yanada","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2024024008","article-title":"How I treat acute myeloid leukemia with differentiation therapy","volume":"145","author":"Issa","year":"2025","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0037-1963(01)90002-2","article-title":"All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia","volume":"38","author":"Fenaux","year":"2001","journal-title":"Semin. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","article-title":"Acute promyelocytic leukemia: From highly fatal to highly curable","volume":"111","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Winer, E.S., and Stone, R.M. (2019). Novel therapy in Acute myeloid leukemia (AML): Moving toward targeted approaches. Ther. Adv. Hematol., 10.","DOI":"10.1177\/2040620719860645"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1254\/jphs.14R15CP","article-title":"Molecular Mechanisms of the Antileukemia Activities of Retinoid and Arsenic","volume":"126","author":"Nitto","year":"2014","journal-title":"J. Pharmacol. Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"104822","DOI":"10.1016\/j.exphem.2025.104822","article-title":"Advances in RAR\u03b1 fusion genes in acute promyelocytic leukemia","volume":"149","author":"Zhang","year":"2025","journal-title":"Exp. Hematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"113451","DOI":"10.1016\/j.ejmech.2021.113451","article-title":"Overview of all-trans-retinoic acid (ATRA) and its analogues: Structures, activities, and mechanisms in acute promyelocytic leukaemia","volume":"220","author":"Liang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1158\/0008-5472.CAN-11-3159","article-title":"The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA","volume":"72","author":"Rabellino","year":"2012","journal-title":"Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4227","DOI":"10.1091\/mbc.e10-05-0449","article-title":"Arsenic-Induced SUMO-Dependent Recruitment of RNF4 into PML Nuclear Bodies","volume":"21","author":"Geoffroy","year":"2010","journal-title":"Mol. Biol. Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.1210\/en.2009-0868","article-title":"Small Ubiquitin-Like Modifier-2 Modification of Retinoic Acid Receptor-\u03b1 Regulates Its Subcellular Localization and Transcriptional Activity","volume":"150","author":"Zhu","year":"2009","journal-title":"Endocrinology"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Liquori, A., Iba\u00f1ez, M., Sargas, C., Sanz, M.A., Barrag\u00e1n, E., and Cervera, J. (2020). Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene. Cancers, 12, Correction in Cancers 2021, 13, 3440.","DOI":"10.3390\/cancers13143440"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1182\/blood.V92.8.2712","article-title":"Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia","volume":"92","author":"Dombret","year":"1998","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Gasparovic, L., Weiler, S., Higi, L., and Burden, A.M. (2020). Incidence of Differentiation Syndrome Associated with Treatment Regimens in Acute Myeloid Leukemia: A Systematic Review of the Literature. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103342"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1182\/blood-2008-07-168617","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors","volume":"113","author":"Montesinos","year":"2009","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamaoncol.2021.5206","article-title":"Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia","volume":"8","author":"Kutny","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"107567","DOI":"10.1016\/j.leukres.2024.107567","article-title":"Distinctive features associated with differentiation syndrome in acute promyelocytic leukemia in patients treated by all-trans retinoic acid and arsenic trioxide","volume":"145","author":"Cingelova","year":"2024","journal-title":"Leuk. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/bjh.18618","article-title":"Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy\u2014A retrospective, single-centre study","volume":"201","author":"Singh","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s12032-010-9462-y","article-title":"Recurrent differentiation syndrome or septic shock? Unresolved dilemma in a patient with acute promyelocytic leukemia","volume":"28","author":"Jeddi","year":"2010","journal-title":"Med. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.leukres.2004.05.006","article-title":"Role of all-trans-retinoic acid (ATRA) in the consolidation therapy of acute promyelocytic leukaemia (APL)","volume":"29","author":"Gupta","year":"2005","journal-title":"Leuk. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e13542","DOI":"10.1200\/jco.2015.33.15_suppl.e13542","article-title":"A phase II study of bexarotene + GM-CSF in refractory AML and high risk MDS","volume":"33","author":"Norsworthy","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"6567","DOI":"10.1200\/jco.2006.24.18_suppl.6567","article-title":"A phase I trial of bexarotene, a retinoid X receptor agonist, in relapsed or refractory non-M3 acute myeloid leukemia (AML)","volume":"24","author":"Tsai","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"E103","DOI":"10.1002\/ajh.23735","article-title":"A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML","volume":"89","author":"Welch","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s12032-007-9035-x","article-title":"Differentiation syndrome in non-M3 acute myeloid leukemia treated with the retinoid X receptor agonist bexarotene","volume":"25","author":"DiNardo","year":"2008","journal-title":"Med. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1111\/cas.12484","article-title":"TET2 as an epigenetic master regulator for normal and malignant hematopoiesis","volume":"105","author":"Nakajima","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/leu.2013.337","article-title":"The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases","volume":"28","author":"Solary","year":"2014","journal-title":"Leukemia"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11899-021-00619-3","article-title":"IDH Inhibitors in AML\u2014Promise and Pitfalls","volume":"16","author":"McMurry","year":"2021","journal-title":"Curr. Hematol. Malign-Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and Azacitidine in IDH1 -Mutated Acute Myeloid Leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Cerchione, C., Romano, A., Daver, N., DiNardo, C., Jabbour, E.J., Konopleva, M., Ravandi-Kashani, F., Kadia, T., Martelli, M.P., and Isidori, A. (2021). IDH1\/IDH2 Inhibition in Acute Myeloid Leukemia. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.639387"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination with Azacitidine for Newly Diagnosed Acute Myeloid Leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"107077","DOI":"10.1016\/j.leukres.2023.107077","article-title":"Efficacy and tolerability of isocitrate dehydrogenase inhibitors in patients with acute myeloid leukemia: A systematic review of clinical trials","volume":"129","author":"Aiman","year":"2023","journal-title":"Leuk. Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/bloodadvances.2022009411","article-title":"Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML","volume":"7","author":"Fenaux","year":"2023","journal-title":"Blood Adv."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1001\/jamaoncol.2024.2662","article-title":"Contemporary Management of Acute Myeloid Leukemia","volume":"10","author":"Venugopal","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.2021014901","article-title":"Enasidenib vs conventional care in older patients with late-stage mutant-IDH2 relapsed\/refractory AML: A randomized phase 3 trial","volume":"141","author":"Montesinos","year":"2023","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/cncr.33477","article-title":"Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach","volume":"127","author":"Kantarjian","year":"2021","journal-title":"Cancer"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1158\/1078-0432.CCR-20-0834","article-title":"Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis","volume":"26","author":"Norsworthy","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation Syndrome Associated with Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1158\/1078-0432.CCR-24-2196","article-title":"FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation","volume":"31","author":"Woods","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Blasi, F., and Bruckmann, C. (2021). MEIS1 in Hematopoiesis and Cancer. How MEIS1-PBX Interaction Can Be Used in Therapy. J. Dev. Biol., 9.","DOI":"10.3390\/jdb9040044"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/onc.2015.174","article-title":"Role of HOXA9 in leukemia: Dysregulation, cofactors and essential targets","volume":"35","author":"Collins","year":"2015","journal-title":"Oncogene"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40164-016-0053-2","article-title":"Mutated NPM1 in combination with overexpression of Meis1 or Hoxa9 is not sufficient to induce acute myeloid leukemia","volume":"5","author":"Wiktorin","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood.2025028357","article-title":"Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: The AUGMENT-101 study","volume":"146","author":"Arellano","year":"2025","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s40265-025-02161-5","article-title":"Revumenib: First Approval","volume":"85","author":"Syed","year":"2025","journal-title":"Drugs"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.24.00826","article-title":"Menin Inhibition with Revumenib for KMT2A -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101)","volume":"43","author":"Issa","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/S1470-2045(24)00386-3","article-title":"Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial","volume":"25","author":"Wang","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/blood-2023-172422","article-title":"A First-in-Human Phase 1 Study of the Menin-KMT2A (MLL1) Inhibitor JNJ-75276617 in Adult Patients with Relapsed\/Refractory Acute Leukemia Harboring KMT2A or NPM1 Alterations","volume":"142","author":"Jabbour","year":"2023","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/hematolrep16020024","article-title":"A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia","volume":"16","author":"Candoni","year":"2024","journal-title":"Hematol. Rep."},{"key":"ref_76","first-page":"1634","article-title":"The improved prognosis of FLT3-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: A realworld study using large-scale electronic health record data","volume":"110","author":"Schwede","year":"2025","journal-title":"Haematologica"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1182\/blood-2012-01-402545","article-title":"Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3\/ITD AML","volume":"120","author":"Sexauer","year":"2012","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/bloodadvances.2018029496","article-title":"Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia","volume":"3","author":"McMahon","year":"2019","journal-title":"Blood Adv."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: Ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1158\/1078-0432.CCR-20-4271","article-title":"FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation","volume":"27","author":"Pulte","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_82","unstructured":"(2026, April 26). VANFLYTA\u00ae (Quizartinib) Prescribing Information. Available online: https:\/\/daiichisankyo.us\/prescribing-information-portlet\/getPIContent?productName=Vanflyta&inline=true."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/ejh.12598","article-title":"Differentiation syndrome in acute myeloid leukemia after treatment with azacitidine","volume":"95","author":"Laufer","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"ref_84","unstructured":"(2026, April 23). NCI Dictionary of Cancer Terms, Available online: https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/differentiation-syndrome."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e2011048","DOI":"10.4084\/mjhid.2011.048","article-title":"Differentiation syndrome in promyelocytic leukemia: Clinical presentation, pathogenesis and treatment","volume":"3","author":"Rego","year":"2011","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1521-6926(03)00043-4","article-title":"Retinoic acid syndrome: Manifestations, pathogenesis, and treatment","volume":"16","author":"Larson","year":"2003","journal-title":"Best Pr. Res. Clin. Haematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.leukres.2013.04.011","article-title":"Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia","volume":"37","author":"Leblebjian","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia","volume":"369","author":"Avvisati","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood.V84.11.3843.bloodjournal84113843","article-title":"Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: Impact of leukocytosis, low-dose chemotherapy, PMN\/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid","volume":"84","author":"Vahdat","year":"1994","journal-title":"Blood"},{"key":"ref_90","first-page":"90","article-title":"Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome","volume":"95","author":"Tallman","year":"2000","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e2011059","DOI":"10.4084\/mjhid.2011.059","article-title":"The differentiation syndrome in patients with acute promyelocytic leukemia: Experience of the pethema group and review of the literature","volume":"3","author":"Montesinos","year":"2011","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.ajkd.2013.02.349","article-title":"KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"61","author":"Palevsky","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4329\/wjr.v6.i8.583","article-title":"Pathophysiology, clinical features and radiological findings of differentiation syndrome\/all-trans-retinoic acid syndrome","volume":"6","author":"Cardinale","year":"2014","journal-title":"World J. Radiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"475","DOI":"10.2214\/ajr.178.2.1780475","article-title":"Radiologic Features of All-Trans-Retinoic Acid Syndrome","volume":"178","author":"Jung","year":"2002","journal-title":"Am. J. Roentgenol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3109\/10428199609054809","article-title":"Retinoic Acid Syndrome: Pulmonary Computed Tomography (CT) Findings","volume":"23","author":"Davis","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.chest.2020.04.052","article-title":"Better with Ultrasound","volume":"158","author":"Hendin","year":"2020","journal-title":"Chest"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.15153","article-title":"Early detection of differentiation syndrome by chest ultrasound in acute promyelocytic leukaemia","volume":"184","author":"Karunakaran","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s40257-022-00673-4","article-title":"New Practical Aspects of Sweet Syndrome","volume":"23","author":"Joshi","year":"2022","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e243615","DOI":"10.1136\/bcr-2021-243615","article-title":"Midostaurin-induced Sweet syndrome in a patient with FLT3-ITD-positive AML","volume":"14","author":"Alkassis","year":"2021","journal-title":"BMJ Case Rep."},{"key":"ref_100","first-page":"1099005","article-title":"A Rare Case of Midostaurin-Associated Sweet\u2019s Syndrome","volume":"2022","author":"Yasin","year":"2022","journal-title":"Case Rep. Hematol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Ghiaur, A., Doran, C., Gaman, M.-A., Ionescu, B., Tatic, A., Cirstea, M., Stancioaica, M.C., Hirjan, R., and Coriu, D. (2024). Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy. Cancers, 16.","DOI":"10.3390\/cancers16061160"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.htct.2021.06.016","article-title":"Acute myocarditis in a patient with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin: A possible relationship with the differentiation syndrome or early anthracycline cardiotoxicity?","volume":"45","author":"Nunes","year":"2023","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1080\/10428194.2016.1253838","article-title":"Recurrent acute myopericarditis without effusion during ATRA induction and ATO salvage of APL: A variant form of the differentiation syndrome?","volume":"58","author":"Vassilakopoulos","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_104","first-page":"e24213","article-title":"A Rare Case of Acute Pericarditis as a Primary Presentation of Differentiation Syndrome","volume":"14","author":"Alyami","year":"2022","journal-title":"Cureus"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4103\/ijp.ijp_811_21","article-title":"Genital ulcers following all-trans-retinoic acid therapy","volume":"55","author":"Saraswat","year":"2023","journal-title":"Indian J. Pharmacol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"449","DOI":"10.25259\/IJDVL_576_2022","article-title":"Oral ulcers and cutaneous rash as manifestations of differentiation syndrome in acute promyelocytic leukaemia","volume":"89","author":"Singh","year":"2022","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ajoc.2018.01.026","article-title":"Two cases of differentiation syndrome with ocular manifestations in patients with acute promyelocytic leukaemia treated with all-trans retinoic acid and arsenic trioxide","volume":"9","author":"Newman","year":"2018","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"323","DOI":"10.18240\/ijo.2021.02.22","article-title":"Exudative hemorrhagic retinopathy related to all-trans retinoic acid differentiation syndrome in a patient with acute promyelocytic leukemia","volume":"14","author":"Tam","year":"2021","journal-title":"Int. J. Ophthalmol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/ICB.0b013e3182618d6c","article-title":"All-trans retinoic acid differentiation syndrome chorioretinopathy","volume":"7","author":"Levasseur","year":"2013","journal-title":"Retin. Cases Brief Rep."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3341\/kjo.2020.0101","article-title":"Ocular Symptom Can Be the First Presentation of Differentiation Syndrome in Acute Promyelocytic Leukemia","volume":"35","author":"Gim","year":"2021","journal-title":"Korean J. Ophthalmol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajh.10156","article-title":"ATRA syndrome with extensive organ infiltration","volume":"71","author":"Kakkar","year":"2002","journal-title":"Am. J. Hematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4103\/ijmpo.ijmpo_36_16","article-title":"Pancreatitis in acute promyelocytic leukemia: Drug-induced or differentiation syndrome?","volume":"38","author":"De","year":"2017","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.2147\/JPR.S305192","article-title":"Differentiation Syndrome with Severe Abdominal Pain During Induction Treatment of Acute Promyelocytic Leukemia: A Case Report","volume":"2021","author":"Yan","year":"2021","journal-title":"J. Pain Res."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Iyer, S.G., Elias, L., Stanchina, M., and Watts, J. (2023). The treatment of acute promyelocytic leukemia in 2023: Paradigm, advances, and future directions. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1062524"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e357","DOI":"10.1016\/S2352-3026(15)00115-5","article-title":"Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: A non-randomised phase 2 trial","volume":"2","author":"Iland","year":"2015","journal-title":"Lancet Haematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective Treatment of Acute Promyelocytic Leukemia with All-Trans-Retinoic Acid, Arsenic Trioxide, and Gemtuzumab Ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jaci.2020.07.001","article-title":"The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection","volume":"146","author":"Copaescu","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"156287","DOI":"10.1016\/j.cyto.2023.156287","article-title":"Emerging aspects of cytokine storm in COVID-19: The role of proinflammatory cytokines and therapeutic prospects","volume":"169","author":"Dharra","year":"2023","journal-title":"Cytokine"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Paranga, T.G., Mitu, I., Pavel-Tanasa, M., Rosu, M.F., Miftode, I.L., Constantinescu, D., Obreja, M., Plesca, C.E., and Miftode, E. (2024). Cytokine Storm in COVID-19: Exploring IL-6 Signaling and Cytokine-Microbiome Interactions as Emerging Therapeutic Approaches. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms252111411"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine Storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.htct.2024.05.002","article-title":"Diagnosis and management of acute promyelocytic leukemia: Brazilian consensus guidelines 2024 on behalf of the Brazilian Association of Hematology, Hemotherapy and Cellular Therapy","volume":"46","author":"Catto","year":"2024","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1182\/blood-2007-07-100669","article-title":"Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin","volume":"111","author":"Montesinos","year":"2008","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/02841859709172077","article-title":"Retinoic acid syndrome-radiological features","volume":"38","author":"Islam","year":"1997","journal-title":"Acta Radiol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: Updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/bjh.16151","article-title":"Differentiation syndrome in acute promyelocytic leukaemia","volume":"187","author":"Stahl","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Mansour, R., Yaseen, A., and Abdel Rahman, Z. (2026). Differentiation Syndrome in Acute Myeloid Leukemia: Molecular Mechanisms, Clinical Spectrum, and Emerging Therapeutic Paradigms. Int. J. Mol. Sci., 27.","DOI":"10.20944\/preprints202601.1529.v1"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","article-title":"Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology","volume":"21","author":"Pollyea","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_128","first-page":"774","article-title":"Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia","volume":"9","author":"Wiley","year":"1995","journal-title":"Leukemia"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1182\/blood-2008-04-150250","article-title":"Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"113","author":"Sanz","year":"2009","journal-title":"Blood"},{"key":"ref_130","first-page":"1","article-title":"Acute kidney failure in differentiation syndrome: A possible complication during therapy with differentiating agents for acute promyelocytic leukemia. A case report","volume":"36","author":"Mirenghi","year":"2019","journal-title":"G. Ital. Nefrol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1111\/bjh.19759","article-title":"Leucocytosis during induction therapy with all-trans-retinoic acid and arsenic trioxide in acute promyelocytic leukaemia predicts differentiation syndrome and treatment-related complications","volume":"205","author":"Cicconi","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e2022027","DOI":"10.4084\/MJHID.2022.027","article-title":"Challenging Management of Severe Differentiation Syndrome in Pediatric Acute Promyelocytic Leukemia Treated with ATRA\/ATO","volume":"14","author":"Molinaro","year":"2022","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/1078155211399163","article-title":"Differentiation syndrome in patients with acute promyelocytic leukemia","volume":"18","author":"Rogers","year":"2012","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_134","first-page":"e50042","article-title":"A Race Against Time: Early-Onset Differentiation Syndrome Following All-Trans-Retinoic-Acid (ATRA) Therapy in Acute Promyelocytic Leukemia (AML-M3)","volume":"15","author":"Ahmad","year":"2023","journal-title":"Cureus"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41419-025-08109-7","article-title":"Anti-inflammatory 25(OH)D(3), a natural steroid hormone, may complement all-trans retinoic acid therapy for differentiation syndrome in acute promyelocytic leukemia","volume":"16","author":"Jambrovics","year":"2025","journal-title":"Cell Death Dis."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1798\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T12:37:34Z","timestamp":1780317454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/11\/1798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":135,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["cancers18111798"],"URL":"https:\/\/doi.org\/10.3390\/cancers18111798","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]}}}